The DDAH/ADMA/NOS pathway

Tran, C. T.L., Leiper, J. M. and Vallance, P. (2003) The DDAH/ADMA/NOS pathway. Atherosclerosis Supplements, 4(4), pp. 33-40. (doi:10.1016/S1567-5688(03)00032-1) (PMID:14664901)

Full text not currently available from Enlighten.

Abstract

An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS), particularly asymmetric dimethylarginine (ADMA) regulate nitric oxide generation in numerous disease states. Two dimethylarginine dimethylaminohydrolase (DDAH) enzymes metabolise ADMA. We and others have postulated that activity of DDAH is a key determinant of ADMA levels in vivo. This review summarises recent advances in the regulation and function of DDAH enzymes and its role in the regulation of nitric oxide generation.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Leiper, Professor James
Authors: Tran, C. T.L., Leiper, J. M., and Vallance, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Atherosclerosis Supplements
Publisher:Elsevier
ISSN:1567-5688
ISSN (Online):1567-5688

University Staff: Request a correction | Enlighten Editors: Update this record